Delivery Order SPE2DB20D2001-SPE2DB25FPNHG
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 19, 2025, by the Defense Logistics Agency (DLA) to supply ORGOVYX 120 MG tablets in quantities of 30 units. The contract is valued at $1,385.52 with a firm fixed price structure and does not utilize a set-aside designation. Performance is scheduled for completion by September 10, 2025, and will be fulfilled at the awardee's Conshohocken, Pennsylvania...
- The U.S. Defense Department's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-unit package) on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for ORGOVYX 120 mg tablets in quantities of 30, with a contract ceiling value of $8,313.12 and an ultimate completion date of August 18, 2025. This is a firm fixed-price, non-set-aside delivery order for pharmaceutical supplies to support federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,385.52 to AmerisourceBergen Drug Corp for 30 units of ORGOVYX 120 mg tablets under a firm fixed-price contract with an ultimate completion date of August 19, 2025. This non-set-aside award was issued on July 29, 2025, and represents a direct procurement through the federal medical supply chain. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and...
- The Defense Logistics Agency awarded a $4,156.56 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the federal government's medical...
- The Defense Logistics Agency awarded a $8,313.12 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit of use packaging). This firm fixed-price contract, with a completion date of September 25, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made through open competition...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $1,385.52 firm fixed-price delivery order from the Defense Logistics Agency on August 25, 2025, for ORGOVYX 120 MG tablets in quantities of 30 units. This award is non-set-aside and competitively awarded, with an ultimate completion date of September 16, 2025. The contract is a delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $8,313.12 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract was awarded on August 4, 2025, with an ultimate completion date of August 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of ORGOVYX 120 mg tablets (30-count unit of use packaging) with a ceiling value of $1,385.52 and a firm fixed price structure. This delivery order, contract number 4569035627, represents a non-competitive, non-set-aside award and is scheduled for completion by August 29, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This competitive award, with no set-aside designation, carries a ceiling value of $1,385.52 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 25, 2025. The award supports the federal government's pharmaceutical procurement needs through...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNHGDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,313.12 on July 29, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 19, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 and extends through December 2026. This prime vendor contract enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's demonstrated capability to compete successfully for federal medical procurements, combined with its extensive pharmaceutical distribution infrastructure, positions it as a critical supplier within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 7/29/25 |